SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing significant social media activity and trending status as investors debate its potential for a short-term squeeze versus long-term viability. The community remains deeply polarized, with some traders actively looking for re-entry points on the dip while skeptics argue that the asset is losing relevance.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is generating significant momentum as its community drives widespread, real-world initiatives ranging from consumer goods to event sponsorships. Investors are actively discussing their conviction in the project's organic growth and are utilizing community-led projects to build and scale the brand.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate whether the asset is finally carving out a macro bottom amid rising on-chain activity and increased institutional integration through custody services. While some community members are calling for a breakout based on bullish technical formations and supply-side fundamentals, others remain skeptical, citing continued underperformance relative to the broader crypto market.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant downward pressure and intense community scrutiny as the token hits multi-year lows, fueling a heated debate among investors regarding its long-term viability and the potential for a deeper capitulation. While some market participants are aggressively accumulating, citing the network's enterprise partnerships and real-world utility as signs of a long-term bottom, many others are expressing frustration over stagnant performance and questioning the project's ability to decouple from broader sector volatility.

General Fusion Group Ltd. engages in the fusion industry, developing practical magnetized target fusion technology that is designed to address the key barriers to commercializing fusion. The company is headquartered in Richmond, Canada.

General Fusion Group Ltd.

General Fusion is trending following its recent Nasdaq debut, with community discourse centered on its long-term path to commercializing fusion technology versus speculative microcap competitors. While some investors remain optimistic about the company's established R&D and institutional backing, others are actively debating the viability of its multi-year roadmap and the risks associated with potential future dilution.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is gaining significant market attention following a strategic partnership with Supermicro to power AI data centers, a move that reinforces its role in the rapidly growing demand for localized, advanced energy solutions. Community sentiment is currently polarized between optimistic investors focusing on the company's microreactor potential and long-term infrastructure pipeline and skeptics who remain concerned about its pre-revenue status and speculative business model.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is currently facing intense community skepticism regarding its structural decay and propensity for reverse splits, while some traders monitor it as a hedge against potential geopolitical escalation and market volatility. Discussion is polarized between those viewing it as a predictable short due to its design flaws and others betting on a sharp spike driven by the potential for a broader market pullback or unexpected instability.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors grapple with conflicting macroeconomic signals, including escalating geopolitical tensions in the Middle East, fluctuating inflation expectations, and shifting Federal Reserve interest rate policy. The community is actively debating gold's role as a safe-haven asset, with many focusing on whether recent price action represents a definitive structural bottom or continued consolidation amid persistent institutional selling and broader market volatility.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors closely monitor Warren Buffett's final correspondence as CEO and prepare for the leadership transition to Greg Abel. The community is actively discussing the strategic management of the company's massive cash pile, its recent equity moves, and the lasting impact of Buffett's investment philosophy on the conglomerate's future.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA approval of Auvelity for the treatment of agitation associated with Alzheimers disease, a major catalyst that positions the company to address a massive underserved market. Community sentiment is overwhelmingly bullish, with investors focusing on the drug's clean safety profile, aggressive peak sales projections, and the potential for a transformative long-term growth trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know

Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.

Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?

Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential

Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential...

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

This $300 Million Biotech May Be Deeply Mispriced: Analyst

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.read more...

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6...

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026...

Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor...

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the...

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Short Interest Up 13.3% in April

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 2,075,273...

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc - ADR

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLNSilence Therapeutics Plc - ADR

Fundamentals

Latest SLN News